HerpeVac Trial for Young Women
Public ClinicalTrials.gov record NCT00057330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evaluation of herpes if it is suspected. Participants will be involved in study related procedures for up to 20 months.
Study identification
- NCT ID
- NCT00057330
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 8,323 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 30 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2003 (Type not available)
- Primary completion
- Aug 22, 2009 (Actual)
- Completion
- Aug 22, 2009 (Actual)
- Last update posted
- Aug 27, 2018
2003 – 2009
United States locations
- U.S. sites
- 67
- U.S. states
- 28
- U.S. cities
- 59
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294 | — |
| GSK Investigational Site | Chandler | Arizona | 85224 | — |
| GSK Investigational Site | Mesa | Arizona | 85203 | — |
| GSK Investigational Site | Mesa | Arizona | 85213 | — |
| GSK Investigational Site | Phoenix | Arizona | 85014 | — |
| GSK Investigational Site | Phoenix | Arizona | 85032 | — |
| GSK Investigational Site | Tempe | Arizona | 85283 | — |
| GSK Investigational Site | Carson | California | 90747 | — |
| GSK Investigational Site | Long Beach | California | 90840 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | San Diego | California | 92108 | — |
| GSK Investigational Site | San Diego | California | 92182 | — |
| GSK Investigational Site | San Francisco | California | 94115 | — |
| GSK Investigational Site | Torrance | California | 90502 | — |
| GSK Investigational Site | Vallejo | California | 94589 | — |
| GSK Investigational Site | Aurora | Colorado | 80045 | — |
| GSK Investigational Site | Athens | Georgia | 30602 | — |
| GSK Investigational Site | Atlanta | Georgia | 30322 | — |
| GSK Investigational Site | Augusta | Georgia | 30912-3500 | — |
| GSK Investigational Site | Satesboro | Georgia | 30460 | — |
| GSK Investigational Site | Chicago | Illinois | 60612-7323 | — |
| GSK Investigational Site | Bloomington | Indiana | 47405 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Arkansas City | Kansas | 67005 | — |
| GSK Investigational Site | Newton | Kansas | 67114 | — |
| GSK Investigational Site | Wichita | Kansas | 67205 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Bardstown | Kentucky | 40004 | — |
| GSK Investigational Site | Lexington | Kentucky | 40536 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70808 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70112 | — |
| GSK Investigational Site | Baltimore | Maryland | 21201 | — |
| GSK Investigational Site | Baltimore | Maryland | 21224 | — |
| GSK Investigational Site | College Park | Maryland | 20742 | — |
| GSK Investigational Site | Boston | Massachusetts | 02118 | — |
| GSK Investigational Site | St Louis | Missouri | 63104 | — |
| GSK Investigational Site | Omaha | Nebraska | 68134 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87131-0001 | — |
| GSK Investigational Site | Brooklyn | New York | 11201 | — |
| GSK Investigational Site | Brooklyn | New York | 11203 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | Rochester | New York | 14620 | — |
| GSK Investigational Site | Rochester | New York | 14642 | — |
| GSK Investigational Site | Stony Brook | New York | 11794-8091 | — |
| GSK Investigational Site | The Bronx | New York | 10461 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27607 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45229 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74105 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Greenville | Pennsylvania | 16125 | — |
| GSK Investigational Site | Grove City | Pennsylvania | 16127 | — |
| GSK Investigational Site | Johnstown | Pennsylvania | 15904 | — |
| GSK Investigational Site | Monongahela | Pennsylvania | 15063 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Wexford | Pennsylvania | 15090 | — |
| GSK Investigational Site | Kingston | Rhode Island | 02881 | — |
| GSK Investigational Site | Nashville | Tennessee | 37232 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Webster | Texas | 77598 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84119 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84132-2405 | — |
| GSK Investigational Site | Seattle | Washington | 98104 | — |
| GSK Investigational Site | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00057330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2018 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00057330 live on ClinicalTrials.gov.